Krsnaa Diagnostics Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹183Cr
- +2.2% YoY
- +4% QoQ
- Net profit
- ₹23Cr
- +4.5% YoY
- +15% QoQ
- Margin
- 32%
- +3 pp YoY
- +3 pp QoQ
The short version
Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone. Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs. 60 crore and PAT increasing 22% YoY to Rs. 24 crore in Q2 FY '26.
From Krsnaa Diagnost.'s Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone.
- Revenue growth expected in higher teens percentage over next couple of years.
- Q4 FY '26 expected to reach Rs. 100 crore quarterly run rate in retail business due to fast expansion.
- Volume growth strategies include introducing wellness packages and advanced test menus, supporting sustainable growth in both PPP and retail channels.
- Rajasthan PPP contract expected to kick in FY '27 onwards, providing significant revenue uptick.
- Overall revenue expected to grow robustly with retail contributing 8-10% in FY '26, accelerating to 15-20% in next financial year.
2 more points from Krsnaa Diagnost.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs. 150 crores to Rs. 170 crores.
- Rs. 80 crores of CAPEX has already been incurred: Rs. 50 crores capitalized and Rs. 30 crores in work-in-progress, mainly for radiology equipment.
- Maharashtra MRI centers are in the final stages of implementation, with assets procured on deferred payments (only 20-25% paid initially).
- Rajasthan expansion involves establishing around 10 labs by December and 25 labs plus 500 centers by Q4.
- Deferred payment and lease models for equipment are being leveraged for capital efficiency.
2 more points from Krsnaa Diagnost.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Maharashtra: 15 MRI centers are under implementation; 10 are near completion and awaiting inauguration.
- Rajasthan: Establishing 10 labs soon; target of 25 labs and 500 centers by December, with remaining centers completed in Q4.
- Pipeline: Several tenders are in various stages across different states; details kept confidential due to competitive nature.
- Attributed to tender timing and government processes, not reduced tender pipeline.
2 more points from Krsnaa Diagnost.'s call on order book
Create a free account to keep reading this call
Krsnaa Diagnost. — Quarterly revenue & net profit
Krsnaa Diagnost. Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 183 | 179 | +2.2% | 176 | +4% |
| Operating profit (EBITDA) | 58 | 52 | +11.5% | 50 | +16% |
| Operating margin | 32% | 29% | +3 pp | 29% | +3 pp |
| Profit before tax | 31 | 28 | +10.7% | 26 | +19.2% |
| Net profit (PAT) | 23 | 22 | +4.5% | 20 | +15% |
| EPS (₹) | 7.16 | 6.80 | +5.3% | 6.03 | +18.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medicare (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnost. Q2 FY26 results?
Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone. Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs. 60 crore and PAT increasing 22% YoY to Rs. 24 crore in Q2 FY '26.
What is Krsnaa Diagnost. share price analysis?
Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnost. planning capital expenditure?
For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs. 150 crores to Rs. 170 crores.
Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
